金双歧联合氨基水杨酸制剂治疗溃疡性结肠炎疗效的Meta分析

Treatment of ulcerative colitis with golden bifid combined with aminosalicylates: a Meta-analysis

目的评价金双歧联合氨基水杨酸类药物对溃疡性结肠炎的治疗价值。方法网络文献检索CNKI、万方数据库、维普、Pub Med和Google Scholar。检索文献截止到2015年7月。由2名评价员独立按照预先指定的纳入和排除标准,进行初步的文献检索。用QUADAS工具对纳入的文献进行筛选和数据提取。采用CMA 2.0软件进行Meta分析。结果初筛出17篇文献,最终纳入8篇文献,共包含619例患者,其中治疗组共计312例患者,对照组共计307例患者。Q检验未发现异质性。分析结果显示,金双歧联合氨基水杨酸类药物治疗组对溃疡性结肠炎的有效率明显高于单用氨基水杨酸类药物治疗组（OR=3.743,95%CI 2.404~5.828,P〈0.01）,可以明显改善治疗效果。结论金双歧和传统氨基水杨酸类制剂合用能明显提高对溃疡性结肠炎的疗效,值得进一步临床研究和推广应用。

Objective To evaluate the efficacy of golden bifid as adjuvant therapies combined with conventional aminosalicylates in patients with ulcerative colitis. Methods A systematic literature search was carried out in the Chinese National Knowledge Infrastructure（CNKI）, Wanfang, Weipu, Pubmed and Google Scholar through July 2015. All studies were evaluated with QUADAS tool and all data were extracted independently by two reviewers. Meta analyses were performed with Comprehensive Meta-Analysis Version 2（CMA2）. Results Initial literature search a total of 17 studies. After assessment, eight studies involving 307 patients that met the inclusion criteria were finally identified. Heterogeneity was not found with Q-test（P〈0.05）. Golden bifid combined with conventional aminosalicylates conferred significant benefit for patients with ulcerative colitis（UC）（OR=3.743, 95% CI 2.404-5.828, P〈0.01）. Conclusions Golden bifid combined with aminosalicylates can achieve better efficacy than monotherapy with aminosalicylates for patients with UC. It worths further clinical research and application.